Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 31:368:m772.
doi: 10.1136/bmj.m772.

Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study

Lindsay A Pearce  1 , Jeong Eun Min  1 , Micah Piske  1 , Haoxuan Zhou  1 , Fahmida Homayra  1 , Amanda Slaunwhite  2 , Mike Irvine  2 , Gina McGowan  3 , Bohdan Nosyk  4   5
Affiliations

Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study

Lindsay A Pearce et al. BMJ. .

Abstract

Objective: To compare the risk of mortality among people with opioid use disorder on and off opioid agonist treatment (OAT) in a setting with a high prevalence of illicitly manufactured fentanyl and other potent synthetic opioids in the illicit drug supply.

Design: Population based retrospective cohort study.

Setting: Individual level linkage of five health administrative datasets capturing drug dispensations, hospital admissions, physician billing records, ambulatory care reports, and deaths in British Columbia, Canada.

Participants: 55 347 people with opioid use disorder who received OAT between 1 January 1996 and 30 September 2018.

Main outcome measures: All cause and cause specific crude mortality rates (per 1000 person years) to determine absolute risk of mortality and all cause age and sex standardised mortality ratios to determine relative risk of mortality compared with the general population. Mortality risk was calculated according to treatment status (on OAT, off OAT), time since starting and stopping treatment (1, 2, 3-4, 5-12, >12 weeks), and medication type (methadone, buprenorphine/naloxone). Adjusted risk ratios compared the relative risk of mortality on and off OAT over time as fentanyl became more prevalent in the illicit drug supply.

Results: 7030 (12.7%) of 55 347 OAT recipients died during follow-up. The all cause standardised mortality ratio was substantially lower on OAT (4.6, 95% confidence interval 4.4 to 4.8) than off OAT (9.7, 9.5 to 10.0). In a period of increasing prevalence of fentanyl, the relative risk of mortality off OAT was 2.1 (95% confidence interval 1.8 to 2.4) times higher than on OAT before the introduction of fentanyl, increasing to 3.4 (2.8 to 4.3) at the end of the study period (65% increase in relative risk).

Conclusions: Retention on OAT is associated with substantial reductions in the risk of mortality for people with opioid use disorder. The protective effect of OAT on mortality increased as fentanyl and other synthetic opioids became common in the illicit drug supply, whereas the risk of mortality remained high off OAT. As fentanyl becomes more widespread globally, these findings highlight the importance of interventions that improve retention on opioid agonist treatment and prevent recipients from stopping treatment.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: funding support from Health Canada SUAP; no financial relationships with any organisations that might have had an interest in the submitted work in the previous three years; no relationships or activities that could appear to have influenced the submitted work.

Figures

Fig 1
Fig 1
All cause mortality by time interval on and off opioid agonist treatment (OAT). British Columbia, 1 January 1996 to 30 September 2018
Fig 2
Fig 2
All cause mortality on and off opioid agonist treatment (OAT) in presence of fentanyl. British Columbia, 1 January 1996 to 30 September 2018
Fig 3
Fig 3
Cause specific mortality by time interval on and off opioid agonist treatment (OAT). British Columbia, 1 January 1996 to 30 September 2018. BNX=buprenorphine/naloxone; MET=methadone
See this image and copyright information in PMC

References

    1. Degenhardt L, Charlson F, Ferrari A, et al. GBD 2016 Alcohol and Drug Use Collaborators The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry 2018;5:987-1012. 10.1016/S2215-0366(18)30337-7 - DOI - PMC - PubMed
    1. Belzak L, Halverson J. The opioid crisis in Canada: a national perspective. Health Promot Chronic Dis Prev Can 2018;38:224-33. 10.24095/hpcdp.38.6.02 - DOI - PMC - PubMed
    1. British Columbia Coroners Service. Fentanyl-detected illicit drug overdose deaths: January 1, 2012 to January 31, 2019. 2019. https://www2.gov.bc.ca/assets/gov/birth-adoption-death-marriage-and-divo....
    1. Zoorob M. Fentanyl shock: The changing geography of overdose in the United States. Int J Drug Policy 2019;70:40-6. 10.1016/j.drugpo.2019.04.010 - DOI - PubMed
    1. Gomes T, Tadrous M, Mamdani MM, Paterson JM, Juurlink DN. The burden of opioid-related mortality in the United States. JAMA Netw Open 2018;1:e180217. 10.1001/jamanetworkopen.2018.0217 - DOI - PMC - PubMed

Publication types

MeSH terms